Companies Dominating the Cardiovascular Clinical Trials Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH.
- Edwards Lifesciences Corporation.
- Siemens Healthineers AG
Furthermore, industries playing vital role in providing clinical trials of cardiovascular facilitating advanced technologies and AI integration to execute smooth and accurate process. Key players dominating cardiovascular clinical trials market include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cardiovascular clinical trials is evaluated at USD 6.19 billion.
The cardiovascular clinical trials market size was over USD 5.91 billion in 2024 and is poised to exceed USD 12.45 billion by 2037, growing at over 5.9% CAGR during the forecast period i.e., between 2025-2037. The market growth can be attributed to rising incidence of cardiac disorders like cardiac arrest, stoke, and coronary artery diseases.
North America industry is estimated to hold largest revenue share of 34% by 2037, influenced by increase in R&D expenditure that drives demand for clinical trials, especially in the cardiovascular field.
The major players in the market are AstraZeneca, AbbVie Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, and others.
